Investor
TCG Crossover
Palo Alto · United States
TCG Crossover is a science-driven investment firm that supports private and public biotechnology companies developing transformative medicines.
Stage
Series A–Growth
Sectors
Digital Health
Cheque
Not confirmed
Invests in
3 countries
Sectors
Invests in
About
This firm focuses on supporting the translation of cutting-edge science into products that improve human health. They provide patient capital from closed-end funds to support visionary entrepreneurs leveraging scientific breakthroughs. The team collaborates with a network of scientific advisors and operational executives to help portfolio companies navigate drug development challenges. Their unique structure allows them to support companies for the long term throughout their entire lifecycle.
How to approach
Submit business plans or creative ideas to the firm's general information email address.
Portfolio · 5 · tap a company to read about it
Recent deals
- 2026-06Ollin BiosciencesSeries BLed
- 2026-06Ollin BiosciencesSeries B
- 2024-11AdcendoSeries B
- 2024-09VicebioSeries B
- 2024-07Beacon TherapeuticsSeries B
- 2024-05Pheon TherapeuticsSeries B
- 2023-06Upstream BioSeries B
- 2023-06AlkeusSeries B
- 2022-06Upstream BioSeries A
- 2022-01Eikon TherapeuticsSeries B
- 2021-11Arbor BiotechnologiesSeries BLed
- 2021-10ShouTiSeries B
- 2021-09Obsidian TherapeuticsSeries B
- 2021-06SynthekineSeries B
- 2021-05Affinia TherapeuticsSeries B